Amanote Research
Register
Sign In
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-14-1170
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
October 15, 2014
Authors
H. Gao
K. Li
H. Tu
X. Pan
H. Jiang
B. Shi
J. Kong
H. Wang
S. Yang
J. Gu
Z. Li
Publisher
American Association for Cancer Research (AACR)
Related search
Radiofrequency Ablation for Hepatocellular Carcinoma Induces Glypican-3 Peptide-Specific Cytotoxic T Lymphocytes
International Journal of Oncology
Cancer Research
Oncology
Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through ERK Signaling Pathway
International Journal of Oncology
Cancer Research
Oncology
Recombinant Soluble Glypican 3 Protein Inhibits the Growth of Hepatocellular Carcinoma in Vitro
International Journal of Cancer
Cancer Research
Oncology
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells
PLoS ONE
Multidisciplinary
Utility and Limitations of Glypican-3 Expression for the Diagnosis of Hepatocellular Carcinoma at Both Ends of the Differentiation Spectrum
Modern Pathology
Forensic Medicine
Pathology
An Anti–glypican 3/Cd3 Bispecific T Cell–redirecting Antibody for Treatment of Solid Tumors
Science Translational Medicine
Medicine
Development of GPC3-specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Regulation of T Helper 17 by Bacteria: An Approach for the Treatment of Hepatocellular Carcinoma
International Journal of Hepatology
Hepatology
